Patent №
US 11,749,394
Granted
2023-09-05
Filed 2021
Owner
BAXALTA INCORPORATED
+1 more
Lab
—
AI components
3
ml · planning · evo
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
17374315
Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.
AI classification
Ownership
BAXALTA INCORPORATED
assignment · 626040377
TAKEDA PHARMACEUTICAL COMPANY LIMITED
assignment · 626040630
Assignors
KUCHIMANCHI, KAMESWARA RAO, LOEW-BASELLI, ALEXANDRA, SPOTTS, GERALD DICKEY, OH, MYUNGSHIN, HALE, MICHAEL DON, WOLFSEGGER, MARTIN
On an employer assignment, the assignors are typically the inventors.